So far the genetic studies have not identified NQO2 gene variants predominantly expressed in AD patients or related to the pharmacogenomics of AD therapy, although one study reported the involvement of an exon 3 missense variant of NQO2 in cognitive decline [68]. Here, NQO2 is linked to Mental deterioration.